JPMorgan Downgrades DaVita (DVA) to Underweight, Negatively Revises EPS Estimate

JPMorgan downgraded DaVita (NYSE: DVA) from Neutral to Underweight with a price target of $51.00 (from $66.00).

Analyst Gary Taylor cites lacking visibility into the company's commercial mix for the downgrade. The analyst comments "DVA has refused to publicly disclose its total number of AKF-subsidized commercial patients. Until we can receive greater clarity to the contrary, we advise investors to Underweight DVA shares."

FY 2017 EPS estimate remains at $3.61, FY 2018 EPS estimate falls from $3.77 to $3.52 and FY 2019 EPS estimate falls from $4.24 to $3.74.

For an analyst ratings summary and ratings history on DaVita click here. For more ratings news on DaVita click here.

Shares of DaVita closed at $59.82 Friday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Stifel Downgrades Saipem (SPM:IM) (SAPMY) to Hold
• Uber Inc. (UBER) PT Raised to $96 at Tigress Financial Partners